Ministry of Education, Culture, Sports, Science and Technology of Japan Malic enzyme 1 (ME1) is a multifunctional protein involved in glycolysis, the citric acid cycle, NADPH production, glutamine metabolism, and lipogenesis. It is overexpressed in various cancers. We examined the expression of ME1 in 119 oral squamous cell carcinomas (OSCCs) using immunohistochemistry. Malic enzyme 1 expression was moderate to strong in 57 (48%) OSCCs and correlated with pT, pN, clinical stage, and histological grade. In 37 cases with prognostic evaluation, moderate to strong ME1 expression indicated a worse prognosis than did weak ME1 expression. Malic enzyme 1 knockdown or inactivation by lanthanide inhibited cell proliferation and motility and suppressed the epithelial-mesenchymal transition in HSC3 human OSCC cells. Knockdown of ME1 also shifted energy metabolism from aerobic glycolysis and lactate fermentation to mitochondrial oxidative phosphorylation, and the redox status from reductive to oxidative. In a mouse tumor model, lanthanide suppressed tumor growth and increased survival time. These findings reveal that ME1 is a valid target for molecular therapy in OSCC.
presence of oxygen) was discovered by Otto Warburg. 11, 12 Most cancer cells enhance glycolysis uncoupled with oxidative phosphorylation, even though glycolysis yields lower amounts of ATP from glucose than oxidative phosphorylation. 13 Cancer cells also often metabolize glutamine to produce enough intermediates (eg, lipids, nucleic acids, and amino acids) for construction of biological components. 14 In normal human cells, glutamine is converted to a-ketoglutarate, which enters the TCA cycle. Glutamine is used for ATP production and the synthesis of nucleic acid, lipids, and other amino acids. 15, 16 Cytoplasmic ME1 decarboxylates malate to form pyruvate and ultimately NADPH. 17 In cancer cells, pyruvate generated in this manner is utilized for lactate fermentation. 18, 19 Because wild-type p53 represses ME1 expression, ME1 overexpression is associated with cancers carrying mutated p53. 20 Epithelial-mesenchymal transition has been strongly implicated in the disease progression and poor prognosis of head and neck squamous cell carcinomas. 21 Epithelial-mesenchymal transition is associated with decreased expression of epithelial cell-cell adhesion molecules, such as E-cadherin or claudin-4, and increased expression of mesenchymal intermediate fiber, vimentin.
In this study, we examined the role of ME1 in OSCC. Malic enzyme 1 is thought to link energy metabolism, redox status, and EMT specifically in cancer and is a putative molecular target for OSCC treatment.
| MATERIALS AND METHODS

| Surgical specimens
Surgical specimens from 46 primary OSCCs treated surgically at Nara
Medical University Hospital (Kashihara, Japan) were randomly selected. Tumor stages and histological grades were determined by using the UICC's TNM classification system. 22 The personal information of the consenting patients was anonymized by the personal information staff. All procedures were carried out in accordance with the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government and approved by the Ethics Committee of Nara Medical University (Approval No. 937).
| Tissue arrays
The OSCC tissue array slides were obtained from US Biomax (Rockville, MD, USA). Slides were immunostained with anti-ME1 antibody (Abnova, Taipei City, Taiwan), and the association between clinicopathological parameters and ME1 expression levels was determined.
| Immunohistochemistry
Formalin-fixed, paraffin-embedded surgical specimens were cut into 4-lm sections. Consecutive 4-lm sections were immunohistochemically stained by using the immunoperoxidase technique described previously. 23 The sections were incubated with 0.5 lg/mL anti-ME1
antibody or anti-p53 antibody (DO-1; Santa-Cruz Biotechnology, Santa Cruz, CA, USA) for 2.5 hour at room temperature. To enhance p53 immunoreactivity, the sections were boiled 3 times in a micro- were purchased from Dako (Osaka, Japan) as were glucose-free DMEM and the ME inhibitor lanthanide (used at 1 lmol/L).
25,26
Mitochondria were stained with MitoGreen solution (Takara Bio, Kusatsu, Japan) and observed by fluorescence microscopy (Zeiss, Tokyo, Japan).
| Cell proliferation and cell infiltration
To assess cell proliferation, cell numbers were determined by using an autocytometer, (CDA-1000; Sysmex, Kobe, Japan). To assess cell infiltration, wound healing assays were carried out. The cell migration area was measured on digitally captured images. In some experiments, cells received lanthanide for 48 hour at 37°C.
| Animal models
Male 5-week-old BALB/cSlc-nu/nu mice were purchased from Japan SLC (Shizuoka, Japan 
| Reverse transcription-PCR
Total RNA (1 lg) was used for synthesizing cDNA by using a ReverTra Ace quantitative PCR RT kit (Toyobo, Osaka, Japan). Polymerase chain reaction was carried out as specified by the provider. The PCR products were electrophoresed on 2% agarose gels and visualized by using ethidium bromide. The primer sets are listed in Table 1 . Primers were synthesized by Sigma-Genosys. 
| Statistical analysis
| Relationship between ME1 expression and clinicopathological parameters in OSCC
Examination of 119 OSCCs showed that ME1 expression significantly correlated with T-factor, N-factor, and clinical stage ( Table 2) . As the cancers progressed, the expression of ME1
increased. In terms of histological grade, ME1 expression was higher in well-differentiated OSCCs than in OSCCs with highgrade histology.
| Relationship between ME1 expression and disease prognosis in OSCC
Although unrelated to tumor recurrence (Table 2) , ME1 expression significantly correlated with the patient's prognosis (Table 3) . In a follow-up study of 37 OSCC patients, 1 of 22 (5%) with ME1 weak expression died, whereas 4 of 15 (27%) with moderate to strong ME1 expression died. Mean survival time was also shorter in patients with moderate to strong ME1 expression than in those with weak ME1 expression. A survival analysis using the Kaplan-Meier method showed that patients with moderate to strong ME1 expression had significantly worse prognosis than did those with weak ME1 expression (Figure 2 ).
| Effect of ME1 knockdown on proliferation and ME1 inactivation on motility
Knockdown of ME1 inhibited the proliferation of HSC3 cells in medium containing 100 or 200 (but not 0 or 450) mg/dL glucose ( Figure 3A) . In a wound healing assay, the HSC3 cell-covered area of the wound was decreased to 38% from 85% by treatment with ME inhibitor lanthanide ( Figure 3B ). Lanthanide treatment inhibited invasion of HSC3 cells into a type IV collagencoated membrane by 52% as determined in an in vitro invasion assay ( Figure 3C ). mRNA levels increased, and snail and vimentin protein levels decreased ( Figure 3E ).
T A B L E 1 Sequences of RT-PCR primers used in this study
Knockdown of ME1 increased the protein levels of PKM (glycolysis), G6PD (PPP), and ACC (TCA), whereas those of GLUD1 (glutaminolysis) were not altered ( Figure 3F ). suggests that HSC3 cells use ME1-generated pyruvate, rather than glycolysis-generated pyruvate, for lactate fermentation in the absence of glucose. Hence, ME1 depletion might suppress pyruvate production and lactate fermentation in glucose-free conditions, in turn increasing the amount of energy generated by the TCA cycle and oxidative phosphorylation.
| Effect of ME1 knockdown on redox status
For assessing the effect of shifting energy metabolism on the redox state, we determined the GSH/GSSG ratio (GSH%) in ME1-depleted HSC3 cells ( Figure 5B ). The GSH% was higher when glucose was present, compared with glucose-free conditions. Knockdown of ME1 decreased the GSH% regardless of glucose concentration. Thus, ME1 knockdown enhanced the oxidative stress in HSC3 cells. Malic enzyme 1 knockdown also increased the mitochondrial area by 90%
( Figure 5C ).
| Effect of ME1 inactivation on tumor growth in an animal model
We finally examined the effects of ME1 inactivation on tumor growth. Lanthanide (0.5 lmol/kg body weight, injected i.p. 8 times at 2-day intervals) suppressed tumor growth by 45% ( Figure 6A ). It also improved survival: the mortality rate decreased from 100% (5/5 mice) to 60% (3/5 mice) ( Figure 6B ), and the 50% survival period increased from 28 days to 39 days during the 40 days of observation. In Figure 6 (C-G), MIB1 positivity (cell proliferation), lactate concentration, CD44 mRNA expression (stemness), and the vimentin/Ecadherin mRNA ratio (EMT) were reduced in the tumor tissue of lanthanide-treated mice compared with control mice, whereas the GSH/GSSG ratio (oxidative phosphorylation-associated oxidative stress) was increased. Tumor stages and histological grades were determined according to the UICC TNM classification system. 22 NS, not significant.
| DISCUSSION
T A B L E 3
Relationship between the expression of malic enzyme 1 (ME1) and mortality and survival time in patients with oral squamous cell carcinoma (n = 37) Several observations suggest that ME1 is a relevant therapeutic target. First, ME1 plays a role in acquisition of EMT phenotype through the PPAR signaling pathway, which upregulates yes-associated protein and tafazzin. 32 Yes-associated protein and tafazzin interacts with Snail/Slug to control stem cell function and expression of the mesenchymal phenotype. 33 Second, ME1 reduces the antitumor effects of radiation. 34 Third, hepatocellular carcinomas overexpressing ME1 have reduced overall and progression-free survival rates compared with those with normal ME1 levels. 31 Finally, as shown here, ME1 expression correlated with disease progression, dedifferentiation, and shorter survival times in OSCC.
ME1 expression
Repression of ME1 expression by wild-type p53 has been reported, as has ME1 overexpression in cells expressing mutant p53. 20 Our immunohistochemical data showed no connection between the expression of these proteins in cell-based observations;
however, owing to the limits of immunohistochemical analysis, p53 involvement in ME1 expression in OSCC cannot be entirely excluded. Malic enzyme 1 expression has also been linked to EMTassociated KRAS mutations. 31 Mutant K-Ras upregulates ME1 in hepatocellular carcinomas 31 and induces radiation resistance in nonsmall-cell lung cancers. 35 KRAS, however, is not mutated in HSC3
cells. Other regulators of ME1 expression include the canonical wnt signaling pathway in breast cancers, 36 a high-fat diet in the intestinal epithelium and hepatocytes, 37 and PPAR/EGR4. 32 Although a highfat diet and PPAR-EGR4 contribute to lipogenesis, upregulation of ME1 did not induce lipogenesis in HSC3 cells (data not shown). HSC3 cells and i.p. injected with lanthanide (LnCl 3 ) (0.5 lmol/kg body weight) or PBS (control) 8 times at 2-day intervals. Tumor diameter was measured. Each group included 5 mice. B, Mice were treated as in panel A. Survival curves were generated by using the Kaplan-Meier method. Each group included 5 mice. C-G, Mice were treated as in panel A, and the indicated parameters were measured in the tumor tissue of mice killed at week 3. C, Proliferative status was determined by MIB1 immunohistochemistry. D, Lactate fermentation was assessed by measuring lactate concentrations. E, Redox status was assessed by determining glutathione/oxidized glutathione (GTH/GSSG) ratios. F, Stemness was assessed by measuring CD44 mRNA levels. G, As an indicator of the epithelial-mesenchymal transition, the vimentin/E-cadherin mRNA ratio (Vim/ECD) was determined. Error bars (Student's t-test) show SD (n = 5) 
